First Manhattan’s Novo Nordisk NVO Stock Holding History

First Manhattan’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,247	Closed	-$369K	–	778
2025 Q4	$369K	Sell	7,247 -243	-3%	-$12.4K	﹤0.01%	613
2025 Q3	$416K	Buy	7,490 +190	+3%	+$11.1K	﹤0.01%	577
2025 Q2	$504K	Buy	7,300 +59	+0.8%	+$4.01K	﹤0.01%	535
2025 Q1	$511K	Sell	7,241 -225	-3%	-$18.6K	﹤0.01%	496
2024 Q4	$642K	Buy	7,466 +243	+3%	+$26.3K	﹤0.01%	459
2024 Q3	$860K	Buy	7,223 +16	+0.2%	+$2.13K	﹤0.01%	395
2024 Q2	$1.03M	Buy	7,207 +237	+3%	+$31.4K	﹤0.01%	358
2024 Q1	$895K	Buy	6,970 +96	+1%	+$11.4K	﹤0.01%	388
2023 Q4	$711K	Buy	6,874 +1,948	+40%	+$193K	﹤0.01%	425
2023 Q3	$448K	Hold	4,926	–	–	﹤0.01%	507
2023 Q2	$399K	Hold	4,926	–	–	﹤0.01%	537
2023 Q1	$392K	Sell	4,926 -410	-8%	-$29.1K	﹤0.01%	548
2022 Q4	$361K	Buy	5,336 +958	+22%	+$56.2K	﹤0.01%	577
2022 Q3	$218K	Hold	4,378	–	–	﹤0.01%	674
2022 Q2	$243K	Hold	4,378	–	–	﹤0.01%	677
2022 Q1	$243K	Hold	4,378	–	–	﹤0.01%	728
2021 Q4	$245K	Sell	4,378 -584	-12%	-$31.6K	﹤0.01%	703
2021 Q3	$238K	Buy	4,962 +26	+0.5%	+$1.26K	﹤0.01%	705
2021 Q2	$206K	Hold	4,936	–	–	﹤0.01%	730
2021 Q1	$166K	Buy	4,936 +1,538	+45%	+$54.8K	﹤0.01%	739
2020 Q4	$118K	Sell	3,398 -30	-0.9%	-$1.04K	﹤0.01%	757
2020 Q3	$119K	Sell	3,428 -12,600	-79%	-$420K	﹤0.01%	749
2020 Q2	$524K	Sell	16,028 -172	-1%	-$5.49K	﹤0.01%	481
2020 Q1	$487K	Hold	16,200	–	–	﹤0.01%	471
2019 Q4	$468K	Hold	16,200	–	–	﹤0.01%	540
2019 Q3	$418K	Sell	16,200 -35,000	-68%	-$885K	﹤0.01%	557
2019 Q2	$1.31M	Hold	51,200	–	–	0.01%	395
2019 Q1	$1.34M	Hold	51,200	–	–	0.01%	397
2018 Q4	$1.18M	Hold	51,200	–	–	0.01%	409
2018 Q3	$1.21M	Hold	51,200	–	–	0.01%	440
2018 Q2	$1.18M	Sell	51,200 -1,200	-2%	-$28.5K	0.01%	423
2018 Q1	$1.29M	Hold	52,400	–	–	0.01%	402
2017 Q4	$1.41M	Sell	52,400 -324	-0.6%	-$8.24K	0.01%	401
2017 Q3	$1.27M	Buy	52,724 +1,200	+2%	+$27.1K	0.01%	401
2017 Q2	$1.1M	Hold	51,524	–	–	0.01%	418
2017 Q1	$883K	Hold	51,524	–	–	0.01%	442
2016 Q4	$923K	Hold	51,524	–	–	0.01%	425
2016 Q3	$1.07M	Hold	51,524	–	–	0.01%	412
2016 Q2	$1.39M	Hold	51,524	–	–	0.01%	382
2016 Q1	$1.4M	Hold	51,524	–	–	0.01%	374
2015 Q4	$1.5M	Sell	51,524 -550	-1%	-$15.2K	0.01%	378
2015 Q3	$1.41M	Hold	52,074	–	–	0.01%	373
2015 Q2	$1.43M	Hold	52,074	–	–	0.01%	386
2015 Q1	$1.39M	Sell	52,074 -47,600	-48%	-$1.1M	0.01%	384
2014 Q4	$2.11M	Sell	99,674 -3,000	-3%	-$67K	0.01%	342
2014 Q3	$2.44M	Buy	102,674 +324	+0.3%	+$7.46K	0.01%	325
2014 Q2	$2.36M	Hold	102,350	–	–	0.02%	323
2014 Q1	$2.34M	Hold	102,350	–	–	0.02%	320
2013 Q4	$1.89M	Hold	102,350	–	–	0.01%	339
2013 Q3	$1.73M	Hold	102,350	–	–	0.01%	351
2013 Q2	$1.72M	Buy	+102,350	New	+$1.7M	0.01%	345

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

First Manhattan's NVO Position: Q1 2026 in Review

First Manhattan sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 7,247 shares — an estimated $369K sold.

First Manhattan first reported a position in NVO in Q2 2013 and held it in 51 quarters. The position peaked at $2.44M in Q3 2014. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

First Manhattan reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
First Manhattan sold 7,247 Novo Nordisk shares in Q1 2026, an estimated $369K.
First Manhattan first reported a position in Novo Nordisk in Q2 2013 and held it in 51 quarters.
First Manhattan's Novo Nordisk position peaked at $2.44M in Q3 2014.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.